Health Economics›Non-small cell lung cancer›Adjuvant therapy

Adjuvant therapy

Non-small cell lung cancer · 28 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~8.4 mo	~21.9 mo	~2	~R 573 911 PFS proxy · indirect	11
Osimertinib monotherapy Variant #01	EGFR	R 155 554	28d	—	—	2	R 311 108 PFS proxy	1
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	~13.3 mo	~2	~R 62 509 PFS proxy · indirect	4
Carboplatin and Pemetrexed Variant #01	ALK	R 14 563	21d	~5.6 mo	~13.8 mo	~10	~R 137 601 PFS proxy · indirect	25
Cisplatin and Pemetrexed Variant #01	—	R 13 666	21d	~5.6 mo	~14.1 mo	~4	~R 54 665 PFS proxy · indirect	25
Cisplatin and Pemetrexed Variant #01	ALK	R 13 666	21d	~5.6 mo	~14.1 mo	~4	~R 54 665 PFS proxy · indirect	25
Cisplatin and Vinblastine Variant #01	—	R 9 253	84d	—	—	3	R 13 318 PFS proxy	1
Carboplatin and Gemcitabine (GCb) Variant #01	ALK	R 4 414	21d	~5.6 mo	~10.0 mo	~2	~R 8 829 PFS proxy · indirect	11
Gefitinib monotherapy Variant #01	EGFR	R 4 278	28d	~9.7 mo	~17.0 mo	~2	~R 8 556 PFS proxy · indirect	27
Cisplatin and Gemcitabine (GC) Variant #01	ALK	R 3 933	21d	—	—	6	R 23 595 PFS proxy	1
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	—	—	6	R 23 595 PFS proxy	1
Cisplatin and Vinorelbine (CVb) Variant #01	—	R 3 333	21d	—	79.9 mo	7	R 13 269 PFS proxy	3
Cisplatin and Vinorelbine (CVb) Variant #01	ALK	R 3 333	21d	—	79.9 mo	7	R 13 269 PFS proxy	3
Cisplatin and Vinorelbine (CVb) Variant #01	EGFR	R 3 333	21d	—	79.9 mo	7	R 13 269 PFS proxy	3
Cisplatin and Docetaxel (DC) Variant #05	—	R 3 185	21d	—	—	3	R 9 556 PFS proxy	1
Carboplatin and Vinorelbine Variant #01	ALK	R 1 985	21d	—	~6.7 mo	~3	~R 5 956 PFS proxy · indirect	1
Cisplatin and Etoposide (EP) Variant #22	—	R 1 819	21d	—	—	6	R 10 916 PFS proxy	1
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	—	95.0 mo	9	R 9 222 PFS proxy	1
Cisplatin and Vindesine Variant #01 Partial	—	R 588	84d	—	—	2	R 1 177 PFS proxy	1
Alectinib monotherapy Variant #01	ALK	R 108	28d	~27.0 mo	—	~2	~R 215 PFS proxy · indirect	7
Nivolumab monotherapy Variant #01 Partial	—	—	14d	~4.2 mo	~13.3 mo	~2	—	3
Radiation therapy N/A - radiation	—	—	49d	~5.1 mo	~12.0 mo	—	—	1
UFT monotherapy Variant #04 Partial	—	—	28d	—	—	52	—	1
Placebo Partial	EGFR	—	—	—	—	—	—	2
Placebo Partial	—	—	—	—	—	—	—	2
Tegafur and uracil monotherapy Partial	—	—	—	—	—	—	—	—
Observation Partial	—	—	—	—	60.5 mo	—	—	4
Icotinib monotherapy Variant #01 Partial	EGFR	—	28d	—	—	26	—	2

28 of 28 regimens shown